Literature DB >> 27259921

Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.

Sarah S Burns1, Long-Sheng Chang2,3,4,5,6.   

Abstract

Schwannomas and meningiomas are nervous system tumors that can occur sporadically or in patients with neurofibromatosis type 2 (NF2). Mutations of the Neurofibromatosis 2 (NF2) gene are frequently observed in these tumors. Schwannomas and meningiomas cause significant morbidities, and an FDA-approved medical therapy is currently not available. The development of preclinical animal models that accurately capture the clinical characteristics of these tumors will facilitate the evaluation of novel therapeutic agents for the treatment of these tumors, ultimately leading to more productive clinical trials. Here, we describe the generation of luciferase-expressing NF2-deficient schwannoma and meningioma cells and the use of these cells to establish orthotopic tumor models in immunodeficient mice. The growth of these tumors and their response to treatment can be measured effectively by bioluminescence imaging (BLI) and confirmed by small-animal magnetic resonance imaging (MRI). These and other animal models, such as genetically-engineered models, should substantially advance the investigation of promising therapies for schwannomas and meningiomas.

Entities:  

Keywords:  Allograft; Bioluminescence imaging (BLI); Intranerve; Magnetic resonance imaging (MRI); Meningioma; Neurofibromatosis 2 (NF2) gene; Neurofibromatosis type 2 (NF2); Severe combined immunodeficiency (SCID) mice; Stereotactic; Vestibular schwannoma; Xenograft

Mesh:

Substances:

Year:  2016        PMID: 27259921     DOI: 10.1007/978-1-4939-3615-1_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

Review 2.  CNS Tumors in Neurofibromatosis.

Authors:  Jian Campian; David H Gutmann
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

3.  New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses.

Authors:  Aysha AlSahlawi; Rasha Aljelaify; Malak Abedalthagafi; Amna Magrashi; Mariam AlSaeed; Amal Almutairi; Fatimah Alqubaishi; Abdulellah Alturkistani; Abdullah AlObaid; Mohamed Abouelhoda; Latifa AlMubarak; Nada AlTassan
Journal:  Oncotarget       Date:  2019-09-17

4.  Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.

Authors:  D Bradley Welling; Katharine A Collier; Sarah S Burns; Janet L Oblinger; Edina Shu; Beth A Miles-Markley; Craig C Hofmeister; Mina S Makary; H Wayne Slone; Jaishri O Blakeley; S Alireza Mansouri; Brian A Neff; Robert K Jackler; Amir Mortazavi; Long-Sheng Chang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-08-20

Review 5.  Use of advanced neuroimaging and artificial intelligence in meningiomas.

Authors:  Norbert Galldiks; Frank Angenstein; Jan-Michael Werner; Elena K Bauer; Robin Gutsche; Gereon R Fink; Karl-Josef Langen; Philipp Lohmann
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

Review 6.  Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.

Authors:  Ryota Tamura
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

7.  Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Authors:  Robert Allaway; Steve P Angus; Roberta L Beauchamp; Jaishri O Blakeley; Marga Bott; Sarah S Burns; Annemarie Carlstedt; Long-Sheng Chang; Xin Chen; D Wade Clapp; Patrick A Desouza; Serkan Erdin; Cristina Fernandez-Valle; Justin Guinney; James F Gusella; Stephen J Haggarty; Gary L Johnson; Salvatore La Rosa; Helen Morrison; Alejandra M Petrilli; Scott R Plotkin; Abhishek Pratap; Vijaya Ramesh; Noah Sciaky; Anat Stemmer-Rachamimov; Tim J Stuhlmiller; Michael E Talkowski; D Bradley Welling; Charles W Yates; Jon S Zawistowski; Wen-Ning Zhao
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.